|Articles|June 1, 1999

Clinical and Economic Impact of Breast Cancer Treatment and Prevention in High-Risk Women
Volume 5
Issue 6 Suppl

Participating Faculty

Download PDF: Participating Faculty

Articles in this issue

about 27 years ago

Article

The Economics and Challenges of Breast Cancer in a Managed Care Environment

about 27 years ago

Article

Medical and Economic Impact of Breast Cancer Treatment and Prevention

about 27 years ago

Article

Benefits Foregone: Too Much of the Wrong and Too Little of the Right

about 27 years ago

Article

Breast Cancer: Overview of Current Management Considerations of Economic Impact

about 27 years ago

Article

Breast Cancer Epidemiology: An Overview

about 27 years ago

Article

Overview of Cancer Economics

about 27 years ago

Article

Breast Cancer Stage Cost Analysis in a Managed Care Population

about 27 years ago

Article

The Cost Effectiveness of Tamoxifen in the Prevention of Breast Cancer

about 27 years ago

Article

Question-and-Answer Session

about 27 years ago

Article

Selected Abstracts

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Readability of Hospital Patient Financial Policy Documents

BySamantha Randall, BA,Sumedha Raghu, MS,Ella Cho,Nina Linh Nguyen, MHA,Erin Trish, PhD,Erin L. Duffy, PhD, MPH

July 7th 2026

Participating Faculty

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

AI Chatbots Score Below 28% on Colorectal Cancer Questions

5 Notable FDA Approvals From the First Half of 2026

New Survey Highlights Quality-of-Life Benefits of Dry Eye Disease Treatment

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

JAK Inhibitors Reshaped Alopecia Areata Care, but Long-Term Data Gaps Remain

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Participating Faculty

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

AI Chatbots Score Below 28% on Colorectal Cancer Questions

5 Notable FDA Approvals From the First Half of 2026

New Survey Highlights Quality-of-Life Benefits of Dry Eye Disease Treatment

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

JAK Inhibitors Reshaped Alopecia Areata Care, but Long-Term Data Gaps Remain